MedPath

An Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis

Not Applicable
Completed
Conditions
Meningitis, Cryptococcal
HIV Infections
Registration Number
NCT00002077
Lead Sponsor
Pfizer
Brief Summary

To evaluate the safety and effectiveness of fluconazole as an intravenous dose as initial treatment for acute cryptococcal meningitis followed by oral therapy in AIDS and non-AIDS patients. Lack of satisfactory response will allow increase of dose. Both newly diagnosed and relapsed patients are eligible.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (4)

Cook County Hosp

🇺🇸

Chicago, Illinois, United States

Saint Michael's Med Ctr

🇺🇸

Newark, New Jersey, United States

Cabrini Med Ctr

🇺🇸

New York, New York, United States

SUNY / Health Sciences Ctr at Brooklyn

🇺🇸

Brooklyn, New York, United States

© Copyright 2025. All Rights Reserved by MedPath